These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3305681)

  • 1. Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.
    Messina M; Milani P; Gentile L; Monaco A; Brossa C; Porta M; Camanni F
    J Endocrinol Invest; 1987 Jun; 10(3):291-5. PubMed ID: 3305681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
    Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
    Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
    Reinwein D; Benker G; Lazarus JH; Alexander WD
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes of thyroid hormone concentrations after (131)I therapy in Graves' patients pretreated or not with methimazole.
    Pirnat E; Zaletel K; Gaberscek S; Fidler V; Hojker S
    Nuklearmedizin; 2004 Aug; 43(4):129-34. PubMed ID: 15316580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
    Roti E; Robuschi G; Gardini E; Montermini M; Salvi M; Manfredi A; Gnudi A; Braverman LE
    Clin Endocrinol (Oxf); 1988 Mar; 28(3):305-14. PubMed ID: 3168311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
    Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
    Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.
    Okamura K; Ikenoue H; Shiroozu A; Sato K; Yoshinari M; Fujishima M
    J Clin Endocrinol Metab; 1987 Oct; 65(4):719-23. PubMed ID: 3654917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of propylthiouracil and methimazol on circulating thyroid hormones and various measures of peripheral thyroid hormone effects in thyrotoxic patients.
    Laurberg P; Tørring J; Weeke J
    Acta Endocrinol (Copenh); 1985 Jan; 108(1):51-4. PubMed ID: 3838216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.